A synthetic angiotensin II/ACE2-based hormone shunt controlling experimental hypertension
R activation during hypertension to a synthetic promoter to coordinate the expression of clinically licensed, secretion-engineered, soluble therapeutic angiotensin-converting enzyme 2 (stACE2), which degrades Ang-II and restores normotension. Implantation of microencapsulated ARCH-transgenic human cells into male hypertensive mice restores and maintains normal blood pressure.
Authors
- Maysam Mansouri (ORCID: https://orcid.org/0000-0001-7396-2372)
- Yuqing Xie (ORCID: https://orcid.org/0000-0003-3996-2234)
- Ghislaine Charpin‐El Hamri
- Martin Fussenegger (ORCID: https://orcid.org/0000-0001-8545-667X)
- Christian Müller (ORCID: https://orcid.org/0000-0002-1120-6405)
- Gokberk Unal (ORCID: https://orcid.org/0000-0001-8130-7423)
Institutions
- University of Basel (CH)
- University Hospital of Basel (CH)
- ETH Zurich (CH)
- Instituts Universitaires de Technologie (FR)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-04-11
- DOI
- https://doi.org/10.1038/s41467-026-71796-z
- Primary Topic
- Renin-Angiotensin System Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung